LEXX
Lexaria Bioscience Corp.
NASDAQ · Healthcare · Biotechnology · CA
$14.15
+14.85%Next report
Analyst consensus
- Next report date
- Oct 28, 2026
- EPS estimate
- -$0.90
- Revenue estimate
- $50.0K
Latest reported
- Last report date
- Jul 13, 2026
- EPS actual
- -$0.08
- EPS estimate
- -$0.06
- Revenue actual
- —
- Revenue estimate
- $54.4K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +17.9%
- Revenue beats (12Q)
- 4
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 28, 2026